AbbVie Inc

4 wrz 2026, 23:05 UTC

AbbVie Inc. shares are lower in after-market hours, reflecting cautious market sentiment amid mixed economic signals and a slight uptick in the unemployment rate.

3 wrz 2026, 23:11 UTC

AbbVie Inc. shares are trading higher in after-market hours following positive results from the Phase 3 CERVINO study of etentamig for multiple myeloma.

2 wrz 2026, 23:51 UTC

AbbVie Inc. shares are lower in after-market trading, despite remaining above the 20-day moving average, amid a weaker-than-expected ADP payrolls report.

1 wrz 2026, 23:56 UTC

AbbVie Inc. has filed for a new Skyrizi regimen to treat Crohn's disease. Shares are lower in after-market hours amid broader market pressure from rising oil prices.

31 sie 2026, 23:01 UTC

AbbVie Inc shares are higher in after-market trading, reflecting positive momentum. No specific company news was identified to explain the price movement.

28 sie 2026, 20:08 UTC

AbbVie shares are lower as the company seeks European approval for SKYRIZI. Rising U.S. Treasury yields amid inflation concerns contribute to market declines.

27 sie 2026, 23:01 UTC

AbbVie Inc. seeks European approval for SKYRIZI to treat Crohn's disease. Shares are higher in after-hours trading following a recent dip.

26 sie 2026, 23:02 UTC

AbbVie Inc shares are trading lower in after-market hours, showing volatility after Wednesday's close with no specific news identified to explain the movement.

25 sie 2026, 20:07 UTC

AbbVie Inc shares are higher, supported by favorable macro conditions and lower Treasury yields. The stock is trading near the upper end of its one-month range.

24 sie 2026, 19:36 UTC

AbbVie Inc. shares are trading lower today, having reached a session low earlier. The stock remains above its 20-day moving average.

21 sie 2026, 20:06 UTC

AbbVie Inc is set to present new data on its bispecific antibody at the 2026 World Conference on Lung Cancer, boosting investor sentiment. Shares are higher today.

20 sie 2026, 19:31 UTC

AbbVie shares are lower today, despite Piper Sandler raising its price target to $303 from $298. The decline aligns with broader sector weakness.

19 sie 2026, 23:01 UTC

AbbVie Inc. is lower in after-market trading, driven by declines in the Biotechnology sub-sector. Recent sessions had shown upward momentum.

18 sie 2026, 23:51 UTC

Abbvie Inc shares are trading higher in after-market hours, reflecting resilience amid elevated bond yields and inflation concerns. The stock remains above its 20-day moving average.

17 sie 2026, 23:51 UTC

AbbVie Inc shares are trading lower in after-market hours amid weak broader market sentiment influenced by geopolitical tensions and rising crude oil prices.

14 sie 2026, 19:46 UTC

AbbVie Inc has begun a Phase 2 trial for ABBV-295, yet shares are lower amid negative market sentiment from a decline in U.S. retail sales.

13 sie 2026, 23:21 UTC

Abbvie Inc shares are lower in after-market hours, with no specific news identified for the decline. Initial jobless claims rose unexpectedly today.

12 sie 2026, 20:06 UTC

AbbVie Inc. shares are lower today, continuing a decline since Tuesday's close, despite FDA acceptance of a BOTOX Cosmetic application for jawline contouring.

11 sie 2026, 20:06 UTC

AbbVie shares are higher as BNP Paribas raises the price target to $247. Allergan Aesthetics enhances its Partner Privileges program to boost customer engagement.

10 sie 2026, 23:06 UTC

AbbVie Inc shares are lower in after-market hours amid mixed market sentiment influenced by geopolitical tensions and President Trump's comments on economic pressure.

7 sie 2026, 23:01 UTC

AbbVie Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains near its one-month low.

6 sie 2026, 20:06 UTC

AbbVie Inc shares are lower as bearish sentiment grows in biotech and pharma sectors, with discussions highlighting potential resistance and negative momentum patterns.

5 sie 2026, 19:26 UTC

AbbVie shares are higher as Canada's Drug Agency recommends UBRELVY for migraine treatment. The company also raised its 2026 revenue outlook to $67.60 billion.

4 sie 2026, 23:01 UTC

AbbVie Inc shares are higher in after-market hours following a recommendation for UBRELVY® reimbursement by Canada's Drug Agency, enhancing patient accessibility.

3 sie 2026, 23:06 UTC

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

31 lip 2026, 20:04 UTC

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

30 lip 2026, 22:41 UTC

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

29 lip 2026, 23:06 UTC

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

28 lip 2026, 23:06 UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

27 lip 2026, 19:46 UTC

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.